Starling Oncology, Inc. Warrant
STLNW
26 hedge funds and large institutions have $6M invested in Starling Oncology, Inc. Warrant in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 7 closing their positions.
11% more capital invested
Capital invested by funds: $5.4M → $6M (+$598K)
0.95% less ownership
Funds ownership: 12.32% → 11.37% (-0.95%)
10% less funds holding
Funds holding: 29 → 26 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$202K |
| 2 |
QGA
Q Global Advisors
Fort Worth,
Texas
|
+$131K |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
+$79.1K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$11.3K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Sage Rock Capital Management
New York
|
-$345K |
| 2 |
ECM
Element Capital Management
New York
|
-$287K |
| 3 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$49K |
| 4 |
LA
Linden Advisors
New York
|
-$35K |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$33K |
STLNW Hedge Fund Activity: Q2 2021 in Review
26 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology, Inc. Warrant (STLNW) for Q2 2021, worth a combined $6M — up 11% from $5.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of STLNW and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Kepos Capital, opening a new position worth an estimated $202K. The largest seller was Sage Rock Capital Management, exiting entirely with an estimated $345K sold.
- 26 institutional investors held Starling Oncology, Inc. Warrant (STLNW) as of Q2 2021, down from 29 in Q1 2021.
- Funds reported $6M of Starling Oncology, Inc. Warrant stock for Q2 2021, up 11% quarter-over-quarter.
- 4 funds opened new Starling Oncology, Inc. Warrant positions in Q2 2021 and 7 closed out, a net change of -3 holders.
- The largest Starling Oncology, Inc. Warrant buyer in Q2 2021 was Kepos Capital, an estimated $202K added.
- The largest Starling Oncology, Inc. Warrant seller in Q2 2021 was Sage Rock Capital Management, an estimated $345K sold.
Based on aggregated 13F filings for Q2 2021.